Cambridge, Massachusetts-based Alnylam Pharmaceuticals released positive Phase III data from the ILLUMINATE-A clinical trial of lumasiran in the treatment of primary hyperoxaluria type 1 (PH1).
Media Alert: Webinar on Improving Clinical Trial Performance – October 2015 WHAT: CRO Analytics will host an upcoming webinar in October, “QPIs: What They Are And How They Drive […]